Valuation: Integrity Applications, Inc.

Market Cap 1.13M 1M 935K 852K 1.6M 108M 1.63M 11.31M 4.38M 55.18M 4.23M 4.13M 177M P/E 2024 *
-
P/E 2025 -0.12x
Enterprise Value -2.81M -2.5M -2.34M -2.13M -4.01M -271M -4.06M -28.25M -10.94M -138M -10.56M -10.33M -443M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
92.02%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 55 2026-07-13
Director of Finance/CFO 66 2025-01-27
Chief Operating Officer - 2025-01-31
Director TitleAgeSince
Director/Board Member 56 2023-08-24
Chairman 64 2024-02-12
Director/Board Member 78 2024-06-13
Change 5-day change 1-year change 3-year change Capi.($)
+15.79%+10.00% - - 1.13M
+4.16%+3.04%+49.37%+94.17% 74.41B
-0.61%+0.81%+27.25%+82.72% 59.26B
-2.54%-1.65%+4.86%+31.72% 47.14B
-3.02%-5.20%+27.94%+32.51% 42.91B
+0.31%+3.02%+348.95%+643.82% 44.13B
-1.96%-0.33%+7.04%+99.46% 40.79B
+3.32%+3.49%+10.10%+51.23% 30.77B
-2.77%+2.74%+29.40%+22.50% 29.31B
-4.86%-10.66%-26.27%+330.06% 23.71B
Average +0.77%-0.52%+53.18%+154.24% 43.6B
Weighted average by Cap. -0.35%-0.32%+58.49%+146.09%

Financials

2024 2025
Net sales - -
Net income -22.6M -20.07M -18.77M -17.1M -32.2M -2.18B -32.64M -227M -87.9M -1.11B -84.84M -83M -3.56B -19.39M -17.22M -16.1M -14.68M -27.63M -1.87B -28.01M -195M -75.42M -951M -72.79M -71.21M -3.05B
Net Debt -5.35M -4.75M -4.44M -4.05M -7.62M -515M -7.73M -53.76M -20.81M -262M -20.09M -19.65M -843M -3.94M -3.5M -3.27M -2.98M -5.61M -379M -5.69M -39.56M -15.31M -193M -14.78M -14.46M -620M
Logo Integrity Applications, Inc.
Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
Employees
-